KR20140009196A - 난소암을 치료하기 위한 프로락틴 수용체 길항제 및 화학치료 약물의 이용 - Google Patents

난소암을 치료하기 위한 프로락틴 수용체 길항제 및 화학치료 약물의 이용 Download PDF

Info

Publication number
KR20140009196A
KR20140009196A KR1020137013005A KR20137013005A KR20140009196A KR 20140009196 A KR20140009196 A KR 20140009196A KR 1020137013005 A KR1020137013005 A KR 1020137013005A KR 20137013005 A KR20137013005 A KR 20137013005A KR 20140009196 A KR20140009196 A KR 20140009196A
Authority
KR
South Korea
Prior art keywords
prolactin receptor
receptor antagonist
prolactin
patient
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020137013005A
Other languages
English (en)
Korean (ko)
Inventor
원 와이. 첸
Original Assignee
온코릭스, 아이엔씨.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 온코릭스, 아이엔씨. filed Critical 온코릭스, 아이엔씨.
Publication of KR20140009196A publication Critical patent/KR20140009196A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2257—Prolactin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
KR1020137013005A 2010-11-17 2011-11-16 난소암을 치료하기 위한 프로락틴 수용체 길항제 및 화학치료 약물의 이용 Ceased KR20140009196A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/948,329 US8648046B2 (en) 2009-02-26 2010-11-17 Compositions and methods for visualizing and eliminating cancer stem cells
US12/948,329 2010-11-17
PCT/US2011/061040 WO2012068282A1 (en) 2010-11-17 2011-11-16 Use of prolactin receptor antagonist and chemotherapeutic drug for treating ovarian cancer

Publications (1)

Publication Number Publication Date
KR20140009196A true KR20140009196A (ko) 2014-01-22

Family

ID=45349276

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137013005A Ceased KR20140009196A (ko) 2010-11-17 2011-11-16 난소암을 치료하기 위한 프로락틴 수용체 길항제 및 화학치료 약물의 이용

Country Status (9)

Country Link
US (2) US8648046B2 (https=)
EP (1) EP2640412B1 (https=)
JP (3) JP6306886B2 (https=)
KR (1) KR20140009196A (https=)
CN (2) CN103298481A (https=)
AU (1) AU2011328935B2 (https=)
CA (1) CA2817846A1 (https=)
IL (1) IL226271A (https=)
WO (1) WO2012068282A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013167750A2 (en) * 2012-05-11 2013-11-14 Prorec Bio Ab Method for diagnosis and treatment of prolactin associated disorders
CN105102480B (zh) 2012-12-24 2019-04-16 艾伯维公司 催乳素受体结合蛋白及其用途
KR102359214B1 (ko) 2014-04-04 2022-02-07 델 마 파마슈티컬스 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체
TW201836647A (zh) 2017-04-06 2018-10-16 美商艾伯維有限公司 抗－ｐｒｌｒ抗體藥物軛合物（ａｄｃ）及其用途
EP3707166A4 (en) * 2017-11-06 2021-11-24 Daniel J. Monticello CHEMICAL ANTIGENIC RECEPTOR SYSTEMS WITH NEGATIVE DOMINANT LIGAND
WO2019169330A1 (en) * 2018-03-02 2019-09-06 Oncolix, Inc. Method for treating cancers expressing prolactin receptor
UY39610A (es) 2021-01-20 2022-08-31 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
CN113956356B (zh) * 2021-10-27 2023-05-02 福州迈新生物技术开发有限公司 抗prl蛋白单克隆抗体、细胞系及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1055932A (en) 1975-10-22 1979-06-05 Hematech Inc. Blood substitute based on hemoglobin
DE2616086C2 (de) 1976-04-13 1986-04-03 Dr. Eduard Fresenius, Chemisch-pharmazeutische Industrie KG, 6380 Bad Homburg Substanz zur Verwendung in einem kolloidalen Blutvolumenersatzmittel aus Hydroxyethylstärke und Hämoglobin
EP1079851B1 (en) * 1998-05-12 2007-07-04 Greenville Hospital System Use of anti-prolactin agents to treat cancer
EP2180054A1 (en) * 1999-12-24 2010-04-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
EP1282642B1 (en) * 2000-05-09 2006-09-06 Greenville Hospital System Therapeutic pore-forming peptides
US7001888B2 (en) * 2002-03-29 2006-02-21 Threshold Pharmaceuticals, Inc. Compositions and methods for treating cancer
BR0314106A (pt) 2002-09-11 2005-07-19 Fresenius Kabi De Gmbh Polipeptìdeos hasilados, especialmente eritropoietina hasilada
NZ541122A (en) * 2002-12-26 2008-09-26 Mountain View Pharmaceuticals Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
US8754031B2 (en) * 2004-03-08 2014-06-17 Oncolix, Inc. Use of prolactin receptor antagonists in combination with an agent that inactivates the HER2/neu signaling pathway
US20050238628A1 (en) * 2004-04-08 2005-10-27 Blau Carl A Methods for treating cancer
US7422899B2 (en) * 2005-10-05 2008-09-09 Biogen Idec Ma Inc. Antibodies to the human prolactin receptor
CN100479863C (zh) * 2006-09-06 2009-04-22 中国医学科学院北京协和医院 Cofilin 1与癌症的紫杉烷类化疗药物耐药性的相关性
EP2094291A1 (en) * 2006-12-21 2009-09-02 Novo Nordisk A/S Dimeric prolactin receptor ligands
WO2009089537A2 (en) * 2008-01-11 2009-07-16 Northwestern University Anti-cancer compounds
US8754035B2 (en) * 2009-02-26 2014-06-17 Oncolix, Inc. Compositions and methods for visualizing and eliminating cancer stem cells

Also Published As

Publication number Publication date
JP2016029110A (ja) 2016-03-03
CN106177915A (zh) 2016-12-07
IL226271A (en) 2017-05-29
JP2013544254A (ja) 2013-12-12
US8648046B2 (en) 2014-02-11
WO2012068282A1 (en) 2012-05-24
JP6306886B2 (ja) 2018-04-04
EP2640412B1 (en) 2017-08-02
IL226271A0 (en) 2013-07-31
AU2011328935B2 (en) 2016-08-11
EP2640412A1 (en) 2013-09-25
JP2018062527A (ja) 2018-04-19
AU2011328935A1 (en) 2013-05-30
US20130231286A1 (en) 2013-09-05
CN103298481A (zh) 2013-09-11
US20110065639A1 (en) 2011-03-17
CA2817846A1 (en) 2012-05-24

Similar Documents

Publication Publication Date Title
KR20140009196A (ko) 난소암을 치료하기 위한 프로락틴 수용체 길항제 및 화학치료 약물의 이용
KR101672401B1 (ko) 암 줄기 세포를 가시화하고 제거하기 위한 조성물 및 방법
EP2496948B1 (en) Compositions and methods for detecting plectin-1 as a biomarker for cancer
US20180134752A1 (en) Par1 and par2 c-tail peptides and peptide mimetics
EP3969000B1 (en) Bcl-2 inhibitors for use in the treatment of a bcl-2 mediated cancer carrying the gly101val mutation
JP2011504361A (ja) 肝細胞癌細胞に特異的なペプチドおよびその適用
HK1231759A1 (en) Use of prolactin receptor antagonist and chemotherapeutic drug for treating ovarian cancer
HK1231758A1 (en) Compositions and methods for visualizing and eliminating cancer stem cells
HK1189171A (en) Use of prolactin receptor antagonist and chemotherapeutic drug for treating ovarian cancer
HK1166693A (en) Compositions and methods for visualizing and eliminating cancer stem cells
AU2024252321A1 (en) Administration of a beta-catenin antagonist and methods of use
US20140005119A1 (en) COMPOSITIONS AND METHODS FOR INHIBITING THE ACTIVITY OF P110a MUTANT PROTEINS
EP3984547A1 (en) Peptides for the treatment of cancer
US10201610B2 (en) Interference peptides and use thereof
KR20200068272A (ko) PNA-pHLIP 접합체를 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20130521

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20161019

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20171115

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20180520

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20171115

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20180618

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20180520

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20190628

Appeal identifier: 2018101002550

Request date: 20180618

J301 Trial decision

Free format text: TRIAL NUMBER: 2018101002550; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20180618

Effective date: 20190628

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20190628

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20180618

Decision date: 20190628

Appeal identifier: 2018101002550